EBAG9 is a type III transmembrane protein that is primarily located in the Golgi. EBAG9 is a tumor-associated antigen that is expressed at high frequency in a variety of cancers, such as advanced breast and prostate cancers. While EBAG9 acts to inhibit the growth of receptor-binding cells and induced apoptosis of immune cells, cancer cells may evade immune surveillance. Thus immunodetection of EBAG9 expression can be a negative prognostic indicator. EBAG9 promotes progression of bladder cancer. In rheumatoid arthritis, the deficiency of EBAG9 induces CTL infiltration through failure to evade immune attack, therefore leading to apoptosis of the synovial lining cells. EBAG9 is involved in controlling exocytosis processes. EBAG9 expression plays a role in the progression of oral squamous cell carcinoma. EBAG9 plays a specific role in premature stages of breast cancer carcinogenesis.
Description: EBAG9 Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 207 amino acids (28-213) and having a molecular mass of 23.4 kDa. The EBAG9 protein is fused to a 20 amino acid His-Tag at N-terminus and purified by standard chromatography techniques.
Physical Appearance: Sterile Filtered colorless solution.
Formulation: The EBAG9 protein solution contains 20mM Tris-HCl pH-8, 1mM DTT, 2mM EDTA and 10% glycerol.
Stability: Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Avoid multiple freeze-thaw cycles.